Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off

A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. Drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.